Also known as: Longeveron
Longeveron is a clinical stage biotechnology company developing regenerative medicines and cellular therapies for life-threatening and chronic aging-related conditions. Its lead investigational product is Lomecel-B, and the company focuses on aging-related chronic diseases and conditions.
Longeveron's DMC recommended completing the Phase 2b ELPIS II HLHS trial with no safety concerns; top-line results expected August 2026. The company also appointed a new CEO and announced cost-cutting measures.
Longeveron Inc. announced Phase 2b clinical trial results published in Cell Stem Cell showing laromestrocel improved physical condition in patients with age-related frailty after nine months compared to placebo.
Longeveron Inc. appointed Stephen H. Willard as CEO effective February 11, 2026, replacing interim CEO Than Powell. The appointment comes as the company expects top-line results from its pivotal Phase 2b trial for Hypoplastic Left Heart Syndrome in Q3 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05233774 |
Lomecel-B Effects on Alzheimer's Disease |
COMPLETED | PHASE2 |
| NCT04925024 |
Evaluation of Lomecel-Bâ„¢ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial. |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04629105 |
Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER) |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT03525418 |
Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS) |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT03169231 |
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty |
COMPLETED | PHASE2 |
| NCT02982915 |
Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty |
COMPLETED | PHASE1/PHASE2 |
| NCT02600130 |
Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease |
COMPLETED | PHASE1 |
| NCT02587572 |
Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial |
WITHDRAWN | PHASE2 |
| NCT02398604 |
Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome |
TERMINATED | PHASE1 |
| NCT02065245 |
AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery |
COMPLETED | PHASE1/PHASE2 |
